Prostate
Prostatic adenocarcinoma
The commonest non-skin cancer of elderly men, usually in the posterior (peripheral) prostate; graded by the Gleason system, detected by PSA and biopsy, and spreading to pelvic nodes and the vertebrae.
Causes et facteurs de risque
- Age (rare before 50; found at autopsy in over half of men over 70)
- Androgen receptor sensitivity; germline BRCA2 mutations raise the risk about 20-fold
- Precursor: high-grade prostatic intraepithelial neoplasia (PIN)
Aspect macroscopique
- Firm yellowish nodules, mostly in the posterior region; the gland is not always enlarged.
Au microscope
- Small, irregular, crowded glands with no stroma between them, prominent nucleoli and perineural invasion.
- Gleason grading: scores for the two commonest patterns (each 1–5) are added; higher sums mean more aggressive tumours.
Évolution
- High-grade PIN develops in a group of acini; TMPRSS2–ETS gene fusions are common to both.
- Invasive adenocarcinoma follows, often small and indolent.
- More aggressive tumours spread to pelvic lymph nodes and bone.
Complications
- Urinary obstruction in advanced disease
- Osteoblastic bone metastases, typically in the vertebral column, with back pain
- A rising PSA suggests carcinoma, even within the normal range; transrectal biopsy confirms it
Examens complémentaires
- Prostate-specific antigen (PSA)
- Often raised; used to detect and follow the disease, though not specific to cancer.
- Multiparametric MRI
- Shows suspicious areas and guides biopsy.
- Prostate biopsy
- Confirms carcinoma; the Gleason score (Grade Group) measures how abnormal the glands are.
- Bone scan or PSMA PET
- Metastases, which in bone are typically osteoblastic (bone-forming).
Traitement médicamenteux
- Androgen deprivation therapy (GnRH analogues and antiandrogens): Treatments that remove the androgen drive on which prostate carcinoma depends: GnRH agonists or antagonists shut down testicular testosterone, and antiandrogens block the androgen receptor.
Médicaments à éviter ou à utiliser avec précaution
- 5α-Reductase inhibitors (Avec précaution): The lower PSA can hide a rising cancer unless corrected.
Anatomie concernée
Sujets liés
Rédigé d’après
- Robbins and Cotran Atlas of Pathology, 3rd ed., Ch. 12, The Male Genital Tract, pp. 322–324, figs 12-44 to 12-50
Ressource pédagogique. Ne constitue pas un avis, un diagnostic ou un traitement médical.